CStone Pharmaceuticals proposes share issuance and buy-back mandates

CStone Pharmaceuticals (HKEX:2616) has announced proposals for general mandates to issue and buy back shares, alongside the re-election of retiring directors and re-appointment of its auditor, to be voted on at its Annual General Meeting (AGM). Shareholders will consider granting directors the authority to issue up to 20% of the company's issued shares, excluding treasury shares, and to repurchase up to 10% of issued shares, also excluding treasury shares. As of June 2, 2025 (the Latest Practicable Date), the company had 1,364,397,235 shares in issue (excluding any treasury shares), meaning these mandates could enable the issuance of up to 272,879,447 new shares and repurchase of up to 136,439,723 shares. The AGM will also address the re-election of Dr. Wei Li as a non-executive Director and Ms. Yip Betty Ho as an independent non-executive Director, and the re-appointment of Deloitte Touche Tohmatsu as auditor. The company's board recommends that shareholders vote in favor of all resolutions.